Bowman–Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The Bowman-Birk inhibitor (BBI), a soybean-derived protease inhibitor with well-characterized ability to inhibit trypsin and chymotrypsin activities, has been shown to be an effective suppressor of carcinogenesis and treated in human phase IIa clinical trial. However, the precise mechanisms by which BBI suppresses carcinogenesis are unknown. In this study, we demonstrated that BBI specifically and potently inhibits the proteasomal chymotrypsin-like activity in vitro and in vivo in MCF7 breast cancer cells. Proteasome inhibition by BBI is associated with accumulation of ubiquitinated proteins and the proteasome substrates, p21Cip1/WAF1 and p27Kip1, accompanied with downregulation of cyclin D1 and cyclin E which could arrest cell cycle at G1/S phase. Moreover, BBI suppressed MCF7 cell growth and had a novel effect on the decrease of phosphorylated extracellular signal-related kinases (ERK1/2). However, BBI was unable to inactivate ERK1/2 in the presence of a phosphatase inhibitor or a transcription inhibitor suggesting the involvement of a specific phosphatase. We found an induction of MAP kinase phosphatase-1 (MKP-1) in dose- and time-dependent manner correlated with dephosphorylation of ERK1/2 in BBI-treated MCF7 cells. In addition, BBI exhibited no inhibitory effects on EGF-stimulated activation of ERK1/2 and Akt. Together, we suggested that BBI abates proteasome function and results in upregulation of MKP-1, which in turn suppresses ERK1/2 activity. Our results support the notion that proteasome inhibition by BBI is a novel mechanism that contributes to prevention of cancer and further provides evidence that soybean products have the potential to advance as chemopreventive agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases
Johnson, G. L., & Lapadat, R. (2002) · Science · doi:10.1126/science.1072682 · Cited by 4,295
Sun, H., Charles, C. H., Lau, L. F., & Tonks, N. K. (1993) · Cell · doi:10.1016/0092-8674(93)90383-2 · Cited by 1,156
Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M., & Sherr, C. J. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1571 · Cited by 1,142
Cheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496
Comparative resistance of the 20S and 26S proteasome to oxidative stress
REINHECKEL, T., SITTE, N., ULLRICH, O., KUCKELKORN, U., DAVIES, K. J. A., & GRUNE, T. (1998) · Biochemical Journal · doi:10.1042/bj3350637 · Cited by 447
Blain, S. W., Montalvo, E., & Massagué, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25863 · Cited by 279
Cited by
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Boutros, T., Chevet, E., & Metrakos, P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00106 · Cited by 545
Cicero, A. F. G., Fogacci, F., & Colletti, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13608 · Cited by 317
Plant protease inhibitors: a defense strategy in plants
(2007) · Biotechnology and Molecular Biology Reviews · doi:10.5897/bmbr2007.0006 · Cited by 292
“BBI has been shown to reduce the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1 (Wen et al., 2005).”
BackgroundBioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects.
Malaguti, M., Dinelli, G., Leoncini, E., Bregola, V., Bosi, S., Cicero, A., & Hrelia, S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151121120 · Cited by 180
“The first mechanism proposed for BBI antiproliferative effects consists in its ability to induce the tumor suppressor gene connexin 43 (Cx43) and cell cycle arrest in G1/S phase [28,29].”
BackgroundBioactive Food Peptides in Health and Disease
(2013) · InTech eBooks · doi:10.5772/3318 · Cited by 168
Clemente, A., Sonnante, G., & Domoney, C. (2011) · Current Protein & Peptide Science · doi:10.2174/138920311796391133 · Cited by 63
Metadata
- Authors
- Chen, Y.-W., Huang, S.-C., Lin-Shiau, S.-Y., & Lin, J.-K.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03-03
- Volume
- 26
- Issue
- 7
- Pages
- 1296-1306
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2141431629
- Cited by
- 129
- References
- 8
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.